Highlights Clearside Biomedical, Inc.

Stocks

CLSD.Q

US1850632035

Biotechnology & Medical Research

Delayed OTC Markets Other stock markets 18:23:45 10/06/2026 BST			5-day change	1st Jan Change
0.3000 ^USD	+172.73%		-11.82%	-57.45%

04-08	First Motion for Exclusivity Period Extension Approved For Clearside Biomedical, Inc.	CI
03-26	Humacyte, Inc. Appoints Rick Mcelheny as Senior Vice President of Business Development	CI

Highlights

11-24	Clearside Biomedical Files for Chapter 11 Bankruptcy; Shares Fall	MT
11-24	Clearside Biomedical to pursue sale of its business through voluntary Chapter 11 process	RE
11-24	Clearside Biomedical files for Chapter 11 bankruptcy in US - court filing	RE
11-14	Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
08/08/25	Clearside Biomedical, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI
23/07/25	Clearside Biomedical Announces Approval of XIPERE Suprachoroidal Treatment for Uveitic Macular Edema in Canada	CI
23/07/25	Clearside Biomedical announces approval of Xipere® suprachoroidal treatment for uveitic macular edema in Canada	RE
17/07/25	Clearside Biomedical, Inc. Announces Plan to Explore Strategic Alternatives to Advance Its Proprietary Suprachoroidal Space Delivery Platform and Promising Ophthalmology Pipeline	CI
16/07/25	Clearside Biomedical to Explore Strategic Alternatives	CI
17/06/25	Clearside Biomedical Announces Multiple Presentations to be Featured at the Clinical Trials at the Summit Meeting	CI
14/05/25	Clearside Biomedical, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2025	CI
09/05/25	Clearside Biomedical Data Featured in Six Presentations At Association for Research in Vision and Ophthalmology 2025 Meeting	CI
27/03/25	Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
27/03/25	Clearside Biomedical, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024	CI
20/03/25	Clearside Biomedical, Inc.'s Lead Clinical Program CLS-AX in Wet AMD and Suprachoroidal Delivery Platform Highlighted at the 2025 Wet AMD & Diabetic Eye Disease Summit	CI
06/03/25	Clearside Biomedical Announces Successful End-of-Phase 2 Meeting with the FDA and Alignment on Phase 3 Plans for Suprachoroidal CLS-AX in Wet AMD	CI
20/02/25	Clearside Biomedical?S Asia-Pacific Partner, Arctic Vision, Announces Acceptance of Its New Drug Application for Arcatus® for Regulatory Review in China for the Treatment of Uveitic Macular Edema	CI
10/02/25	Clearside Biomedical Announces Additional Data from the Cls-Ax Oysysy Phase 2B Trial Presented At the Angiogenesis, Exudation, and Degeneration 2025 Meeting	CI
22/01/25	Clearside's Partner Receives NDA Approvals for Uveitic Macular Edema Treatment in Australia, Singapore	MT
22/01/25	Clearside Biomedical, Inc. Announces Its Asia-Pacific Partner, Arctic Vision, Receives Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore	CI
12/11/24	Clearside Biomedical, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2024	CI
07/11/24	Clearside's Partner Arctic Vision Enters Collaboration With Santen Pharma for Uveitic Macular Edema Treatment	MT
22/10/24	Clearside Biomedical, Inc.'s Positive ODYSSEY Wet AMD Data and Suprachoroidal Injection Platform Highlighted in Presentations at Multiple Events During AAO 2024 Annual Meeting	CI
09/10/24	Top Premarket Gainers	MT
09/10/24	Clearside Biomedical Shares Rise After Phase 2B Trial of Potential Eye Degeneration Treatment Shows Positive Data	MT